[HTML][HTML] Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine
J Nagarajah, M Le, JA Knauf… - The Journal of …, 2016 - Am Soc Clin Investig
Radioiodide (RAI) therapy of thyroid cancer exploits the relatively selective ability of thyroid
cells to transport and accumulate iodide. Iodide uptake requires expression of critical genes …
cells to transport and accumulate iodide. Iodide uptake requires expression of critical genes …
Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma
F Grabellus, J Nagarajah, A Bockisch… - Clinical nuclear …, 2012 - journals.lww.com
Purpose: Glucose transporters 1 (GLUT1) facilitates glucose uptake in cancer. An inverse
relationship between I-131 and F-18 fluorodeoxyglucose (FDG) uptake in PET/CT (“flip-flop …
relationship between I-131 and F-18 fluorodeoxyglucose (FDG) uptake in PET/CT (“flip-flop …
Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study
…, JO Barentsz, M Gotthardt, JA Witjes, J Nagarajah - Clinical Cancer …, 2021 - AACR
Purpose: [ 177 Lu]Lu-PSMA-617 radioligand therapy ( 177 Lu-PSMA) is a novel treatment
for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to …
for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to …
[HTML][HTML] Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre) clinical studies
…, SAM van Lith, N Mehra, J Nagarajah… - European journal of …, 2023 - Springer
Introduction Fibroblast activation protein (FAP) is highly overexpressed in stromal tissue of
various cancers. While FAP has been recognized as a potential diagnostic or therapeutic …
various cancers. While FAP has been recognized as a potential diagnostic or therapeutic …
Positron emission tomography/magnetic resonance imaging for local tumor staging in patients with primary breast cancer: a comparison with positron emission …
J Grueneisen, J Nagarajah, C Buchbender… - Investigative …, 2015 - journals.lww.com
Objectives This study aimed to assess the diagnostic performance of integrated positron
emission tomography (PET)/magnetic resonance imaging (MRI) of the breast for lesion …
emission tomography (PET)/magnetic resonance imaging (MRI) of the breast for lesion …
Evaluation of 18F-FDG PET/MRI, 18F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer
…, C Buchbender, J Nagarajah… - European journal of …, 2016 - Elsevier
Objectives To compare the diagnostic performance of 18 F-fluordesoxyglucose positron
emission tomography/magnetic resonance imaging ( 18 F-FDG PET/MRI) with 18 F-FDG PET/…
emission tomography/magnetic resonance imaging ( 18 F-FDG PET/MRI) with 18 F-FDG PET/…
[HTML][HTML] Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment …
…, N Mehra, JA Witjes, M Gotthardt, J Nagarajah… - European journal of …, 2022 - Springer
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic
prostate cancer patients and correlation with treatment outcome | European Journal of …
prostate cancer patients and correlation with treatment outcome | European Journal of …
EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC
…, Z Zhao, SW Lowe, G Lee, I Landa, J Nagarajah… - Cancer discovery, 2019 - AACR
Mutations of EIF1AX, a component of the translation PIC, co-occur with RAS in advanced
thyroid cancers and promote tumorigenesis. EIF1AX-A113splice drives an ATF4-induced …
thyroid cancers and promote tumorigenesis. EIF1AX-A113splice drives an ATF4-induced …
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
…, H Ahmadzadehfar, HJ Biersack, J Nagarajah… - European journal of …, 2014 - Springer
Purpose Renal radiation during peptide receptor radionuclide therapy (PRRT) may result in
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …
Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system
…, T Höller, HJ Biersack, J Nagarajah - Journal of Nuclear …, 2014 - Soc Nuclear Med
The tumor proliferation marker, Ki-67 index, is a well-established prognostic marker in
gastroenteropancreatic neuroendocrine neoplasms (NENs). Noninvasive molecular imaging …
gastroenteropancreatic neuroendocrine neoplasms (NENs). Noninvasive molecular imaging …